Your analysis makes good sense with clear rationality. In particular, the impact of GLP-1s on Obstructive Sleep Apnea (OSA) and subsequently on ResMed’s volumes is a core uncertainty for the years ahead. However, I remain confident that there are much more penetrations of continuous positive airway pressure (CPAP) therapy to people in developed and developing countries in particular.
Having noted the impact of GLP-1s on RMD share price, the price goes up and up as we are worrying and writing.
Looking at RSI (14 & 30 days line) technical indications, it is not in overbought territory yet.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$38.69 |
Change
0.100(0.26%) |
Mkt cap ! $22.45B | |||
| Open | High | Low | Value | Volume |
| $38.70 | $38.80 | $38.59 | $1.905M | 49.24K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 295 | $38.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $38.73 | 135 | 3 |
View Market Depth
| Last trade - 10.42am 18/06/2025 (20 minute delay) ? |
| RMD (ASX) Chart |